A curious cardiologist asks a colleague of mine who uses MCG Technology:” What difference does MCG make?”
My answer:
Tell him that MCG is the only technology that detects, measure quantitatively, and monitor, both forms of heart failure:
The “weak” type - increased myocardial compliance
The “stiff” type - decreased myocardial compliance
Bottom line:
Early detection of Cardiometabolic dysfunctions enables timely lifestyle optimization disease prevention and reversal of the cardiovascular effects of insulin resistance. This is the key to improving the safe and effective early diagnosis of Cardiometabolic functions to promote longer and healthier lives for patients.
💯%! The bast path forward to stop this deadly disease is to detect the metabolic dysfunctions early and apply lifestyle optimization measures to reverse them. Our experience applying MCG Technology in this way has shown that early detection of the effects of insulin resistance will allow safe and effective primary prevention for Cardiometabolic diseases disease reversal. Med 3.0, or burst!
I will address this metabolic issue on Monday and I agree with your point. We do too little too late. In patients with diabetes and chronic kidney disease, the difference between optimal medical therapy and usual care is huge up until 8 years. Putting everyone on OMT thereafter did not close the complication gap at all, probably because of too much damage to functional cells and too much scar formation.
Yes. To stop this, early detection, lifestyle optimization education, and optimal medical therapy combined to reverse early signs of metabolic dysfunctions will stop the relentlessly heart failure, save lives threatened by heart failure.
Finally, the mainstream acknowledges the following (which I have known since I started the journey of creating MCG in the 90’s):
40% of 45 year olds will develop heart failure which has a 75% mortality rate and medium survival of only two years. Medicare spends 30% of its annual budget on paying the costs of treating heart failure patients and the deaths just keep piling up. This needs to stop!
What is The underlying cause of the types of heart failure?
The Metabolic Heart Dysfunction.
Our view:
The legacy Med 2.0 lacks diagnostic tools to detect and quantify metabolic heart dysfunction, especially in its critical early stages where disease reversal is still possible!
MCG shines and saves the day and future of mankind!!! MCG detects the earliest signs of metabolic heart dysfunction and enables timely disease reversal to save lives at much lower costs!
This is the latest in our world:
A curious cardiologist asks a colleague of mine who uses MCG Technology:”What difference does MCG make?”
My answer:
Tell him that MCG is the only technology that detects, measure quantitatively, and monitor, both forms of heart failure:
The “weak” type - increased myocardial compliance
The “stiff” type - decreased myocardial compliance
Among other critical capabilities.
The Bottomline:
Early detection of Cardiometabolic dysfunctions enables timely lifestyle optimization disease prevention and reversal of the cardiovascular effects of insulin resistance. MCG Technology is the key to improving the safe and effective early diagnosis of Cardiometabolic dysfunctions to promote longer and healthier lives for patients for a fraction of the costs the failed legacy med 2.0 demands.
MCG is the tip of the spear to usher in an era of the new world of fundamental digital transformation of medicine for everyone!
A curious cardiologist asks a colleague of mine who uses MCG Technology:” What difference does MCG make?”
My answer:
Tell him that MCG is the only technology that detects, measure quantitatively, and monitor, both forms of heart failure:
The “weak” type - increased myocardial compliance
The “stiff” type - decreased myocardial compliance
Bottom line:
Early detection of Cardiometabolic dysfunctions enables timely lifestyle optimization disease prevention and reversal of the cardiovascular effects of insulin resistance. This is the key to improving the safe and effective early diagnosis of Cardiometabolic functions to promote longer and healthier lives for patients.
💯%! The bast path forward to stop this deadly disease is to detect the metabolic dysfunctions early and apply lifestyle optimization measures to reverse them. Our experience applying MCG Technology in this way has shown that early detection of the effects of insulin resistance will allow safe and effective primary prevention for Cardiometabolic diseases disease reversal. Med 3.0, or burst!
I will address this metabolic issue on Monday and I agree with your point. We do too little too late. In patients with diabetes and chronic kidney disease, the difference between optimal medical therapy and usual care is huge up until 8 years. Putting everyone on OMT thereafter did not close the complication gap at all, probably because of too much damage to functional cells and too much scar formation.
Yes. To stop this, early detection, lifestyle optimization education, and optimal medical therapy combined to reverse early signs of metabolic dysfunctions will stop the relentlessly heart failure, save lives threatened by heart failure.
Med 3.0, or burst!
Once again an amazing article!!
I am curious what are your thoughts of use of metformin when someone has COVID. Is is also improvement due to increased AMPK ?
Diabetics on metformin have a three fold reduction in COVID mortality
https://www.uab.edu/news/research/item/11795-metformin-use-reduces-risk-of-death-for-patients-with-covid-19-and-diabetes
Yes. We actually measure that from patients before and after the start of taking Metformin. The impact is detectable.
Amazing so the indication for use is due to AMPK?
AMPK is a master survival switch. Metformin directly activates it.
Thank you that makes sense. I was wondering if there were any other benefits?
Longer organ survival.
Longer life.
Thank you so much
Most likely. That was the only changed variable.
It's all about mTOR. But that would mean having to pay attention in molecular biology class, which I didn't do, so....
It is a unifying concept that makes understanding chronic illnesses easier
Please share my message below.
Finally, the mainstream acknowledges the following (which I have known since I started the journey of creating MCG in the 90’s):
40% of 45 year olds will develop heart failure which has a 75% mortality rate and medium survival of only two years. Medicare spends 30% of its annual budget on paying the costs of treating heart failure patients and the deaths just keep piling up. This needs to stop!
What is The underlying cause of the types of heart failure?
The Metabolic Heart Dysfunction.
Our view:
The legacy Med 2.0 lacks diagnostic tools to detect and quantify metabolic heart dysfunction, especially in its critical early stages where disease reversal is still possible!
MCG shines and saves the day and future of mankind!!! MCG detects the earliest signs of metabolic heart dysfunction and enables timely disease reversal to save lives at much lower costs!
This is the latest in our world:
A curious cardiologist asks a colleague of mine who uses MCG Technology:”What difference does MCG make?”
My answer:
Tell him that MCG is the only technology that detects, measure quantitatively, and monitor, both forms of heart failure:
The “weak” type - increased myocardial compliance
The “stiff” type - decreased myocardial compliance
Among other critical capabilities.
The Bottomline:
Early detection of Cardiometabolic dysfunctions enables timely lifestyle optimization disease prevention and reversal of the cardiovascular effects of insulin resistance. MCG Technology is the key to improving the safe and effective early diagnosis of Cardiometabolic dysfunctions to promote longer and healthier lives for patients for a fraction of the costs the failed legacy med 2.0 demands.
MCG is the tip of the spear to usher in an era of the new world of fundamental digital transformation of medicine for everyone!
Med 3.0, or burst!
Joseph